Catherine Nguyen

Education
M.P.H, epidemiology and biostatistics, UCLA Fielding School of Public Health; B.S., human biology and society, University of California, Los Angeles
Summary of Experience
Ms. Nguyen specializes in epidemiology, treatment effectiveness, and health outcomes research. She has experience with observational and regulatory studies, including FDA post-authorization safety studies. Ms. Nguyen has used insurance claims, medical chart review, electronic medical records, and other health care data across a range of disease areas, including cancer, cystic fibrosis, COVID-19, depression, and asthma. She has conducted studies to answer research questions related to treatment patterns, comparative effectiveness, drug safety, and health care resource utilization and cost. Prior to joining Analysis Group, Ms. Nguyen worked at the local, state, and federal levels of government, which included assessing community hypertension prevention programs and investigating tuberculosis outbreaks in California. She has presented research at conferences with a variety of stakeholders and published manuscripts in a number of peer-reviewed journals.
-
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis
Thorax, 2024
2024Merlo CA, McGarry LJ, Thorat T, Nguyen C, DerSarkissian M, Muthukumar A, Healy J, Brookhart MA, Rubin JL
HEOR, Epidemiology & Market Access -
Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis
Thorax, 2024
2024Merlo CA, Thorat T, DerSarkissian M, McGarry LJ, Nguyen C, Gu YM, Healy J, Rubin JL, Brookhart MA
HEOR, Epidemiology & Market Access -
A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis
Pulmonary Therapy, 2024
2024Merlo C, Thorat T, McGarry LJ, Scirica CV, DerSarkissian M, Nguyen C, Gu YM, Muthukumar A, Healy J, Rubin JL, Brookhart MA
HEOR, Epidemiology & Market Access -
Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab
Current Medical Research and Opinion, 2022
2022Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y
HEOR, Epidemiology & Market Access -
The acute effects of azithromycin use on cardiovascular mortality as compared with amoxicillin-clavulanate in US Veterans
Pharmacoepidemiology and Drug Safety, 2022
2022DerSarkissian M, Young-Xu Y, Duh MS, Bhak RH, Palmetto N, Mortensen E, Anzueto A, Nguyen C, Cheng M, Frajzyngier V, Park S, Lax A, Weatherby LB, Walker AM
HEOR, Epidemiology & Market Access -
Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
Frontiers in Oncology, 2021
2021Yu KH, Hendifar AE, Alese OB, Draper A, Abdelrahim M, Burns E, Khan G, Cockrum P, Bhak RH, Nguyen C, DerSarkissian M, Duh MS, Bahary N
HEOR, Epidemiology & Market Access -
Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary Disease
International Journal of Chronic Obstructive Pulmonary Disease, 2021
2021Mapel DW, Roberts MH, Sama S, Bobbili PJ, Cheng WY, Duh MS, Nguyen C, Thompson-Leduc P, Van Dyke MK, Rothnie KJ, Sundaresan D, Certa JM, Whiting TS, Brown JL, Roblin DW
HEOR, Epidemiology & Market Access -
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer, 2019
2019Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC
HEOR, Epidemiology & Market Access
-
August 24, 2024
Analysis Group Researchers to Present at ISPE 2024
Event: 40th International Society for Pharmacoepidemiology (ISPE) Annual Meeting
Host: International Society for Pharmacoepidemiology (ISPE)
-
August 26, 2024
-
August 30, 2022